학술논문

EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA-AMYLOID 42 (Aβ42)-SPECIFIC ANTIBODY, IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE
Document Type
Abstract
Source
In Alzheimer's & Dementia: The Journal of the Alzheimer's Association July 2017 13(7) Supplement:P574-P574
Subject
Monday, July 17, 2017: Oral Session: O2-09: Clinical: Clinical Trials Testing Amyloid and Non-Amyloid Targets
Language
ISSN
1552-5260